Purpose: Neuroendocrine tumors (NETs) are now routinely treated by radiopeptide targeted therapy using somatostatin receptor-binding peptides such as Y- and Lu-DOTATOC. The objective of this work was to develop a biokinetics model of Y labelled DOTATOC, which is applied in the therapy of NETs to estimate doses in kidney and tumor.
Methods: A multi-compartment model described by two sets of differential equations, one set for the actual 30-min infusion and the other set for the post-infusion period was developed and activities were measured by liquid scintillation counting in blood (compartment 1) and the urine (compartment 3).